A-List Investor Spotlight
This article was originally published in Start Up
Investors like Imperial Innovations and Jumpstart are stepping up to fill the gap in Series A investing.
You may also be interested in...
Last month's announcement that Pfizer Inc. plans to close its flagship U.K. R&D operations in Sandwich, Kent, is but the latest example of how major shifts in Big Pharma's business and research strategies are exacting a heavy toll on long-established facilities.
Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.